Generic name: Budesonide
Budesonide is a man-made glucocorticoid steroid related to the naturally-occurring hormone, cortisol or hydrocortisone which is produced in the adrenal glands. It is used for treating asthma by inhalation. Glucocorticoid steroids such as cortisol or budesonide have potent anti-inflammatory actions that reduces inflammation and hyper-reactivity (spasm) of the airways caused by asthma. When used as an inhaler, the budesonide goes directly to the inner lining of the inflamed airways to exert its effects.
Generic name: Beclomethasone
Beclomethasone is a synthetic steroid of the glucocorticoid family. The naturally-occurring glucocorticoid (cortisol or hydrocortisone) is produced in the adrenal glands. eclomethasone is used for the control of bronchial asthma in persons requiring continuous treatment. Such patients may include those with frequent asthmatic episodes that require medications to dilate the airways in the lung or those with asthmatic episodes at night.
Generic name: Flunisolide
It is an intranasal and oral inhalation adrenal corticosteroid. It is prescribed in the treatment of seasonal or continuing allergic rhinitis that involves inflammation of the mucous membranes of the nasal passages and for the treatment of asthma.
contraindications It should not be given to patients with allergy to this drug or any of its components or to patients with status asthmaticus or untreated bacterial, viral, or fungal infections of the respiratory tract or nasal mucosa.
Generic name: Montelukast
Montelukast is an oral leukotriene receptor antagonist that is used for the treatment of asthma and seasonal allergic rhinitis (hay fever). Leukotrienes are a group of naturally occurring chemicals in the body that promote inflammation in asthma and seasonal allergic rhinitis and in other diseases in which inflammation is important (such as allergy). They are formed by cells, released, and then bound to other cells that cause inflammation. It is the binding to other cells that stimulates the cells to cause inflammation. Montelukast works in a manner similar to zafirlukast (Accolate), blocking the binding of some leukotrienes to the cells that cause inflammation. Unlike zafirlukast, montelukast does not inhibit CYP2C9 or CYP3A4, two enzymes in the liver that are important in breaking down and eliminating many drugs. Therefore, unlike zafirlukast, montelukast is not expected to affect the elimination of other drugs. The safety and effectiveness of montelukast has been demonstrated in children as young as 6 months of age. It was approved by the FDA in 1998.